RS20050014A - Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof - Google Patents
Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereofInfo
- Publication number
- RS20050014A RS20050014A YUP-2005/0014A YUP20050014A RS20050014A RS 20050014 A RS20050014 A RS 20050014A YU P20050014 A YUP20050014 A YU P20050014A RS 20050014 A RS20050014 A RS 20050014A
- Authority
- RS
- Serbia
- Prior art keywords
- group
- halogen atom
- therapeutic use
- atom
- alkoxy
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- -1 trifluoromethoxy radical Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Pronalazak se odnosi na 1-supstituisane derivate piperazinilacilpiperidina opšte formule (I) gde je n, 1 ili 2; p je 1 ili 2; R1 predstavlja atom halogena; trifluorometil radikal; (C1-C4)alkil; (C1-C4)alkoksi; trifluorometoksi radikal; R2 predstavlja atom vodonika ili atom halogena; R3 predstavlja atom vodonika; grupu -OR5; grupu -CH2R5; grupu -NR6R7; grupu -NR8COR9; grupu -NR8CONR10R11; grupu -CH2NR12R13; grupu -CH2NR8CONR14R15; (C1-C4)alkoksi karbonil; grupu -CONR16R17; ili R3 obrazuje dvostruku vezu izmedju atom ugljenika za koji je vezan i susednog atom ugljenika piperidinskog prstena; R4 predstavlja aromatičnu grupu odabranu od: ove aromatične grupe su ansupstituisane ili mono- ili disupstituisane substituentom odabranim nezavisno od atoma halogena; (C1-C4)alkila; (C1-C4)alkoksi; triflorometil radikala. Pronalazak se takodje odnosi na postupak za dobijanje ovih jedinjenja i njihovu terapeutsku primenu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0207001 | 2002-06-07 | ||
| PCT/FR2003/001685 WO2003104225A1 (fr) | 2002-06-07 | 2003-06-05 | Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS20050014A true RS20050014A (en) | 2007-06-04 |
Family
ID=29724874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20050014A RS52588B (sr) | 2002-06-07 | 2003-06-05 | Supstituisani derivati 1-piperazinilacilpiperidina, njihovo dobijanje i terapeutska primena |
| YUP-2005/0014A RS20050014A (en) | 2002-06-07 | 2003-06-05 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20050014A RS52588B (sr) | 2002-06-07 | 2003-06-05 | Supstituisani derivati 1-piperazinilacilpiperidina, njihovo dobijanje i terapeutska primena |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7468368B2 (sr) |
| EP (2) | EP1513836B1 (sr) |
| JP (2) | JP4437075B2 (sr) |
| KR (1) | KR100970812B1 (sr) |
| CN (1) | CN100448875C (sr) |
| AR (2) | AR040247A1 (sr) |
| AT (2) | ATE336491T1 (sr) |
| AU (2) | AU2003255645A1 (sr) |
| BR (1) | BR0311828A (sr) |
| CA (1) | CA2487840C (sr) |
| CY (2) | CY1107330T1 (sr) |
| DE (2) | DE60305037T2 (sr) |
| DK (2) | DK1513835T3 (sr) |
| EA (1) | EA007501B1 (sr) |
| ES (2) | ES2264001T3 (sr) |
| HK (1) | HK1076110A1 (sr) |
| HR (1) | HRP20041157B1 (sr) |
| IS (1) | IS2302B (sr) |
| MA (1) | MA27233A1 (sr) |
| ME (1) | MEP11508A (sr) |
| MX (1) | MXPA04012341A (sr) |
| NO (1) | NO329669B1 (sr) |
| NZ (1) | NZ537044A (sr) |
| PL (1) | PL208711B1 (sr) |
| PT (2) | PT1513835E (sr) |
| RS (2) | RS52588B (sr) |
| TW (2) | TWI319400B (sr) |
| UA (1) | UA77526C2 (sr) |
| WO (2) | WO2003104226A1 (sr) |
| ZA (1) | ZA200409823B (sr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
| WO2005068445A2 (en) * | 2004-01-08 | 2005-07-28 | Syngenta Participations Ag | Pesticidal heterocyclic dihaloallyl compounds |
| CN1984910A (zh) * | 2004-07-16 | 2007-06-20 | 詹森药业有限公司 | 适用于神经变性疾病治疗的哌啶、哌嗪或者吗啉或它们的7元类似物的二聚化合物 |
| CN101083982A (zh) * | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物 |
| EP1871420A4 (en) * | 2005-04-15 | 2010-09-22 | Univ North Carolina | PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS |
| CL2008000725A1 (es) * | 2007-03-15 | 2008-11-14 | Schering Corp | Compuestos derivados de heterociclos aromaticos; composicion farmaceutica; kit farmceuticos; uso de la composicion y de los compuestos como inhibidores de glucano sintasa para el tratamiento o prevencion del crecimiento de patogenos fungicos en planta y para tratar o prevenir infecciones producidas por hongos. |
| EP2162135A4 (en) * | 2007-05-21 | 2012-02-22 | Reviva Pharmaceuticals Inc | COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS |
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| FR2932482B1 (fr) * | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| FR2932481B1 (fr) | 2008-06-13 | 2010-10-08 | Sanofi Aventis | Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique. |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| EP2498782B1 (en) | 2009-11-12 | 2019-01-09 | Pharmatrophix Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| EP2513057B1 (de) | 2009-12-14 | 2013-09-04 | Merck Patent GmbH | Inhibitoren der sphingosinkinase |
| FR2953836B1 (fr) | 2009-12-14 | 2012-03-16 | Sanofi Aventis | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| FR2953839A1 (fr) * | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| WO2019055966A2 (en) * | 2017-09-18 | 2019-03-21 | Goldfinch Bio, Inc. | PYRIDAZINONES AND METHODS OF USE |
| EP3852533B8 (en) | 2018-09-18 | 2024-07-17 | Gfb (Abc), Llc | Pyridazinones and methods of use thereof |
| EP3858439A1 (en) * | 2020-02-03 | 2021-08-04 | Esteve Pharmaceuticals, S.A. | Amide derivatives having multimodal activity against pain |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU208690B (en) * | 1987-10-26 | 1993-12-28 | Pfizer | Process for producing 1-hjeterocyclic sulfonyl-3-(pyrimidinyl piperazinyl)-propane derivatives and pharmaceutical compositions comprising same |
| FR2747041B1 (fr) * | 1996-04-05 | 1998-05-22 | Cird Galderma | Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies |
| US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| FR2803593B1 (fr) | 2000-01-06 | 2002-02-15 | Sanofi Synthelabo | Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant |
-
2003
- 2003-05-06 UA UA20041210010A patent/UA77526C2/uk unknown
- 2003-06-05 AU AU2003255645A patent/AU2003255645A1/en not_active Abandoned
- 2003-06-05 DK DK03757108T patent/DK1513835T3/da active
- 2003-06-05 US US10/516,704 patent/US7468368B2/en active Active
- 2003-06-05 DK DK03757109T patent/DK1513836T3/da active
- 2003-06-05 WO PCT/FR2003/001686 patent/WO2003104226A1/fr active IP Right Grant
- 2003-06-05 BR BR0311828-2A patent/BR0311828A/pt not_active IP Right Cessation
- 2003-06-05 ES ES03757109T patent/ES2264001T3/es not_active Expired - Lifetime
- 2003-06-05 ME MEP-115/08A patent/MEP11508A/xx unknown
- 2003-06-05 JP JP2004511295A patent/JP4437075B2/ja not_active Expired - Fee Related
- 2003-06-05 RS RS20050014A patent/RS52588B/sr unknown
- 2003-06-05 RS YUP-2005/0014A patent/RS20050014A/sr unknown
- 2003-06-05 NZ NZ537044A patent/NZ537044A/en not_active IP Right Cessation
- 2003-06-05 EP EP03757109A patent/EP1513836B1/fr not_active Expired - Lifetime
- 2003-06-05 EP EP03757108A patent/EP1513835B1/fr not_active Expired - Lifetime
- 2003-06-05 AT AT03757108T patent/ATE336491T1/de active
- 2003-06-05 MX MXPA04012341A patent/MXPA04012341A/es active IP Right Grant
- 2003-06-05 DE DE60305037T patent/DE60305037T2/de not_active Expired - Lifetime
- 2003-06-05 CA CA2487840A patent/CA2487840C/en not_active Expired - Fee Related
- 2003-06-05 US US10/516,808 patent/US7294628B2/en not_active Expired - Lifetime
- 2003-06-05 KR KR1020047019860A patent/KR100970812B1/ko not_active IP Right Cessation
- 2003-06-05 PT PT03757108T patent/PT1513835E/pt unknown
- 2003-06-05 PL PL374729A patent/PL208711B1/pl not_active IP Right Cessation
- 2003-06-05 DE DE60307632T patent/DE60307632T2/de not_active Expired - Lifetime
- 2003-06-05 WO PCT/FR2003/001685 patent/WO2003104225A1/fr active IP Right Grant
- 2003-06-05 EA EA200401470A patent/EA007501B1/ru not_active IP Right Cessation
- 2003-06-05 PT PT03757109T patent/PT1513836E/pt unknown
- 2003-06-05 JP JP2004511296A patent/JP4441401B2/ja not_active Expired - Fee Related
- 2003-06-05 ES ES03757108T patent/ES2271637T3/es not_active Expired - Lifetime
- 2003-06-05 CN CNB038188082A patent/CN100448875C/zh not_active Expired - Fee Related
- 2003-06-05 AU AU2003255644A patent/AU2003255644B2/en not_active Ceased
- 2003-06-05 AT AT03757109T patent/ATE325122T1/de active
- 2003-06-06 TW TW092115443A patent/TWI319400B/zh not_active IP Right Cessation
- 2003-06-06 AR ARP030102018A patent/AR040247A1/es active IP Right Grant
- 2003-06-06 TW TW092115416A patent/TWI283671B/zh not_active IP Right Cessation
- 2003-06-06 AR ARP030102017A patent/AR040246A1/es active IP Right Grant
-
2004
- 2004-12-02 IS IS7579A patent/IS2302B/is unknown
- 2004-12-03 MA MA27980A patent/MA27233A1/fr unknown
- 2004-12-03 ZA ZA200409823A patent/ZA200409823B/en unknown
- 2004-12-06 HR HR20041157 patent/HRP20041157B1/xx not_active IP Right Cessation
- 2004-12-06 NO NO20045331A patent/NO329669B1/no not_active IP Right Cessation
-
2005
- 2005-11-19 HK HK05110460.5A patent/HK1076110A1/xx not_active IP Right Cessation
-
2006
- 2006-08-03 CY CY20061101094T patent/CY1107330T1/el unknown
- 2006-11-15 CY CY20061101660T patent/CY1105784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS20050014A (en) | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | |
| DK0794949T3 (da) | Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler | |
| AU679761B2 (en) | 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives as 5HT1A ligands | |
| HK1069395A1 (en) | Phthalazinone derivatives 2,3 | |
| NZ536734A (en) | Spiroindolinepiperidine derivatives | |
| EP1775289A4 (en) | NEW IMIDAZOLIDINE DERIVATIVES | |
| AR023188A1 (es) | Derivados de 1,4-diazabiciclo[3.2.2]nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica | |
| TW200738667A (en) | Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof | |
| ATE388958T1 (de) | 4'-c-substituierte 2-haloadenosinderivate | |
| HRP20090159T1 (en) | Use of glucosidase inhibitors for therapy of mucovisidosis | |
| PH12015501098A1 (en) | Antituberculous composition comprising oxazole compounds | |
| TW200607808A (en) | Pyrido-pyrimidine derivatives, preparation thereof and application thereof | |
| AU2003254852A8 (en) | Fused heterocyclic compounds as peptidase inhibitors | |
| TW200500339A (en) | Pyrrolidine derivatives, and process for the preparation | |
| NO20071008L (no) | Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater | |
| NO20061832L (no) | Karboksamidderivat av amidtype | |
| NO20062936L (no) | Fremgangsmate for fremstilling av N-alkyl-2(hydroksy-4-benzoyl)-3-benzofuraner og dets mellomprodukter derav | |
| BG104447A (en) | Biphenylamidine derivatives | |
| TW200510361A (en) | Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives | |
| TNSN06337A1 (en) | 6-substituted pyridoindolone derivatives production and therapeutic use thereof | |
| RS20050018A (en) | Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors | |
| MY139258A (en) | Carbamoyl-type benzofuran derivatives | |
| UA88925C2 (en) | 4-nitroimidazole derivatives | |
| BG104037A (en) | 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy | |
| MX2007003159A (es) | Derivados piridinicos de indolin-2-ona, prepracion y uso terapeutico de los mismos. |